Monthly MS injection aims to halt disability progression

NCT ID NCT03362294

Terminated Disease control Sponsor: Mapi Pharma Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a long-acting form of glatiramer acetate (GA Depot) given as a monthly shot to people with primary progressive multiple sclerosis (PPMS). The goal was to see if it could safely slow down worsening disability. The trial was stopped early, but it involved 30 adults aged 18-65 with PPMS who received either 25 mg or 40 mg of the drug every four weeks for nearly three years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis primary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Locations

Mapi Pharma Research site 01

Tel Aviv, Israel
Mapi Pharma Research site 06

Rehovot, Israel
Mapi Pharma Research site 07

Jerusalem, Israel
Mapi Pharma Research site 08

Petah Tikva, Israel
Mapi Pharma Research site 09

Haifa, Israel
Mapi Pharma Research site 20

Chisinau, Moldova
Mapi Pharma Research site 22

Chisinau, Moldova